Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KMV, Williamson DE, Gregg E, Zhang P. Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making. 2002 Jan 1;22(5):S80-91.
Von Scheele BG, Sherrill EH, Gilsenan AW, Devlin P. Therapeutic interchangeability of levothyroxine. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
McKenna SP, Doward LC, van Assche D. Diabetic foot ulcers: a patients' perspective. Proc Br Psychol Soc. 2001;9(1):70.
Hoogeveen EK, Rothman KJ. Hyperhomocysteinemia increases the risk of death in type 2 diabetes. Cardiovasc Rev Rep. 2001;22:207-12.
Pladevall-Vila M. Relationships between obesity, cardiovascular risk factors and insulin resistance. Presented at the European Congress on Clinical Investigation; 2001.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.
Wirén L, Whalley D, McKenna SP, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52.
Moore LL, Singer MR, Bradlee ML, Rothman KJ, Milunsky A. A prospective study of the risk of congenital defects associated with maternal obesity and diabetes mellitus. Epidemiology. 2000 Jan 1;11(6):689-94.
Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.
Castellsague J, Perez GS, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf. 1998 Feb 1;18(2):117-23.
McKenna S, Doward LC. Measuring quality of life in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Oct;45(4):507-8.
Wagner JD, Carlson CS, O'Brien TD, Anthony MS, Bullock BC, Cefalu WT. Diabetes mellitus and islet amyloidosis in cynomolgus monkeys. J Am Assoc Lab Anim. 1996 Feb;48(1):36-41.
Holmes SJ, McKenna SP, Doward LC, Hunt SM, Shalet SM. Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrinology and metabolism. 1995 Jan 1;2(1):63-9.
McKenna SP, Doward LC. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. Pharmacoeconomics. 1994 Nov 1;6(5):434-41.
Hunt SM, McKenna SP, Doward LC. Preliminary report on the development of a disease-specific instrument for assessing quality of life of adults with growth hormone deficiency. Acta Endocrinol. 1993 Jun 1;128(Suppl 2):37-40.
Wagner JD, Welles EG, Bell-Farrow AD, Anthony MS, Cefalu WT. Non-ketotic hyperglycemia and obesity preceding insulinopenic state in aged monkeys (macaca fascicularis). Diabetes. 1991;40(Suppl 40):219A.
Bode HH, Rothman KJ, Danon M. Linkage of thyroxine-binding globulin deficiency to other x-chromosome loci. J Clin Endocrinol Metab. 1973 Jan 1;37(1):25-9.